4.7 Article

A ketogenic diet consumed during radiotherapy improves several aspects of quality of life and metabolic health in women with breast cancer

Journal

CLINICAL NUTRITION
Volume 40, Issue 6, Pages 4267-4274

Publisher

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.clnu.2021.01.023

Keywords

Blood parameters; EORTC-QLQ30; KETOCOMP; Nutrition

Ask authors/readers for more resources

The study showed that ketogenic diets (KDs) have potential benefits for women with early-stage breast cancer undergoing radiotherapy, including significant improvements in emotional functioning, social functioning, sleep quality, future perspectives and systemic therapy side effects. The KD group also showed improvements in metabolic health biomarkers compared to the standard diet (SD) group, indicating a safe and beneficial impact of KD during radiotherapy for breast cancer patients.
Background & aims: Ketogenic diets (KDs) have been proposed as complementary nutritional treatments for cancer patients. Because it is important to gain knowledge about the safety of KDs adopted during cancer therapy, we studied the effects of KDs on quality of life and blood parameters in women with early-stage breast cancer undergoing radiotherapy. Methods: A total of 29 patients consuming a KD were compared to 30 patients consuming their standard diet (SD) with respect to EORTC-QLQ30 questionnaire scores and different metabolic and hormonal blood parameters that were obtained prior to, in the middle of and at the end of radiotherapy. Baselineto-end differences were assessed using Wilcoxon tests, and longitudinal changes were analyzed using linear mixed effects models. Results: Compared to the SD, women consuming a KD experienced significant improvements in emotional functioning, social functioning, sleep quality, future perspectives and systemic therapy side effects (all p-values <0.01). While breast symptoms increased significantly in both groups, the increase was less pronounced in the KD group. There was no hint of a detrimental effect of the KDs on either liver or kidney function; in contrast, biomarkers of metabolic health (gamma-glutamyl-transpeptidase, creatinine, triglycerides, IGF-1, free T3) significantly improved in the KD, but not the SD group. Conclusions: These data support the hypothesis that consuming a KD during radiotherapy is safe for women with breast cancer and has the potential to improve quality of life and metabolic health. ClinicalTrials.gov identifier: NCT02516501. 0 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available